Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
SET-Plan Conference 2019 Helsinki (SET-Plan Helsinki)

Framework: Horizon 2020 — Societal Challenges
Programme: Secure, clean and efficient energy
Action type: Coordination and support actions
Countries involved: Finland
Call: Support to the Finnish Presidency Conference on the European Strategic Technology Plan (SET-Plan) 2019 (H2020-IBA-ENERGY-SETPLAN-2020, 2020)
Start date: 2019-09-01
End date: 2020-02-29
Duration (months): 6.0
Total project cost (EUR): 400000.0
EU funding (EUR): 250000.0
Participants: 3
Project status: CLOSED

This proposal addresses the Work Programme 2018-2020 for Secure, Clean and Efficient Energy. In particular it addresses section “Support to the Finnish Presidency Conference on the European Strategic Technology Plan (SET-Plan) 2019” of the chapter “Transforming the Energy Sector Through Digitalisation” subchapter “Grants to Identified Beneficiaries”. The European Strategic Energy Technology Plan (SET-Plan) was established to accelerate the transformation of the European energy system and to bring new low-carbon energy technologies to market. It identifies actions for research and innovation throughout the whole innovation chain. SET-Plan conferences offer an opportunity for decision-makers, researchers and stakeholders to get together and evaluate the progress made towards achieving the SET-Plan’s goals. The 13th SET-Plan Conference will take place on 13-15 November 2019 in Helsinki, Finland. The conference venue is the conference wing of the Finlandia Hall. The organisers of the conference are Ministry of Economic Affairs and Employment of Finland (TEM), the Prime Minister’s Office of Finland (VNK), VTT Technical Research Centre of Finland Ltd (VTT) and the European Commission.

Keywords: set plan,energy technology,clean energy
Fossil Fingerprinting and Identification of New Denisovan remains from Pleistocene Asia (FINDER)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: The study of the human past
Panel description: Archaeology, history and memory
Countries involved: Austria,Germany
Call: ERC Starting Grant (ERC-2016-STG, 2016)
Start date: 2017-06-01
End date: 2024-05-31
Duration (months): 84.0
Total project cost (EUR): 1999292.0
EU funding (EUR): 901262.5
Participants: 2
Project status: SIGNED

Scientific analyses of ancient biomolecules (proteins, DNA, hard tissues) have transformed our knowledge of archaic hominins present in Eurasia prior to the expansion of modern humans from Africa. In 2010, a finger bone discovered in Siberia was assigned using DNA to a new, previously unknown human group, the Denisovans. The Denisovans interbred with both Asian Neanderthals and AMH over the past 100,000 years; their geographic distribution is now thought to have stretched from the Siberian steppes to the tropical forests of SE Asia and Oceania. Despite their broad spatio-temporal range, the Denisovans are only known from 4 tiny bones, all from a single Siberian cave. This patchy knowledge of an entire human population significantly limits our ability to test hypotheses and interpretative models concerning major issues in human evolution, such as the routes and timing of people movements across Asia, the nature and frequency of interaction between archaic indigenous groups and migratory modern humans, the mechanisms leading to the demise of archaic lineages and eventual sole dominance of our species on Earth. This project aims to rectify the dearth of Denisovan fossils by applying a novel combination of cutting-edge scientific methods (collagen fingerprinting, radiocarbon dating and ancient DNA analyses) designed to identify, date and genetically characterize new human fossils, with a particular emphasis on the discovery of Denisovan remains. Instead of only focusing on the few morphologically identifiable human bones, a groundbreaking high-throughput approach will target bulk collections of unidentified bone fragments (n=30,000) from ~20 Asian sites dating to between 100,000-10,000 years. Ultimately, the goal is to expand our understanding of the Denisovans, reveal their geographic range, age, genetic variation and archaeological signature. In addition to solving the puzzles of ancient population history, this research has the potential to decode the patchwork that makes modern humans who we are today, physically, behaviourally and genetically.

Keywords: denisovans,palaeolithic,neanderthals,homo sapiens,archaeological science,radiocarbon dating,ancient dna,collagen fingerprinting
Encapsulated eukaryotic ribosome assembly (Glowsome)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Advanced grants
Action type: ERC actions
Panel: Molecules of Life: Biological Mechanisms, Structures and Functions
Panel description: Molecular biology, biochemistry, structural biology, molecular biophysics, synthetic and chemical biology, drug design, innovative methods and modelling
Countries involved: Germany
Call: ERC Advanced Grant (ERC-2016-ADG, 2016)
Start date: 2017-09-01
End date: 2022-08-31
Duration (months): 60.0
Total project cost (EUR): 2000000.0
EU funding (EUR): 2000000.0
Participants: 1
Project status: CLOSED

The production of fully functional ribosomes is vital for every cell, with failure causing human diseases called ribosomopathies. Eukaryotic ribosome assembly is catalyzed by ~200 assembly factors that guarantee efficient and accurate production of ribosomal subunits along a temporally and spatially ordered pathway. About one third of these factors are utilized in the formation of the earliest biogenesis intermediate, termed 90S pre-ribosome or small subunit processome. Recent insight into the 90S structure from a eukaryotic thermophile, Chaetomium thermophilum, has provided a first spatial impression on this most sophisticated process, which includes co-transcriptional RNA folding and processing, and incorporation of ribosomal proteins. Our key discovery was that the nascent ribosomal RNA, which if linear would form a long thread, is co-transcriptionally mounted into a mold formed by a highly interconnected RNA-protein scaffold on the 90S pre-ribosome. This finding raises a novel concept in RNA biology that nascent RNA folds and matures in a protected environment, which is reminiscent of protein folding that can also occur in folding chambers. I plan to challenge the idea that the 90S particle indeed encapsulates the RNA transiently, in order to protect it from unproductive interactions, allowing stepwise folding and maturation in a cascade of interdependent reactions and the involvement of energy-consuming enzymes. The groundbreaking aim of this proposal is to decipher how these processes occur in an encapsulated environment, using C. thermophilum as a model organism. This high-risk project will depend on the successful establishment of novel assays that recapitulate eukaryotic ribosome assembly in vitro, exploiting the thermostable nature of the 90S pre-ribosome. Mechanistic insight into ribosome biogenesis will lead to a better understanding of how this multifaceted process is linked to other key cellular pathways and development of diseases including cancer.

Keywords: ribosome biogenesis,thermophilic eukaryote,90s pre ribosome,rrna folding,rrna processing
ENTERPRISE RESOURCE PLANNING (ERP) SOLUTION INTERCONNECTING DEPARTMENTS’ SOFTWARE IN HEALTHCARE FACILITIES (HEMACONN)

Framework: Horizon 2020 — Industrial Leadership
Programme: Information and Communication Technologies
Action type: SME instrument
Countries involved: Italy
Call: Open Disruptive Innovation Scheme (H2020-SMEINST-1-2016-2017, 2016)
Start date: 2016-08-01
End date: 2016-11-30
Duration (months): 4.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

HEMACONN is an innovative Enterprise Resource Planning (ERP) tool, especially designed for Healthcare Facilities (HCF), leveraging a considerable reduction in institutional administrative processes time (80%) and costs (50%) and guaranteeing better process management and higher productivity. Thanks to its revolutionary “Plug-in-and-Go” architecture, HEMACONN will be introduced as a UNIQUE solution automatically interconnecting all fragmented departmental software solutions installed on HCFs’ systems, without the need for any post-installation integration/customization efforts and costs. This novel approach will provide administrations with a comprehensive administrative tool to streamline and reduce unnecessary costs, optimize operational time of administrative activities, and annul the probability of human error, delays, shortages, and misdistribution. HEMACONN is verticalized over the Microsoft Dynamics NAV platform, and therefore, it offers, in addition to Microsoft’s standard management tools, Eid’s specialized healthcare modules, Artificial Intelligence features (auto learning and pattern recognition), flexible workflow engine, and integrated RFID Applications. The global ERP software market is expected to reach €45Bn by 2020, registering a CAGR of 7.2% during 2014-2020 with healthcare being ranked as the fourth market sector in terms of ERP investment. This project aligns with the European Commission’s eHealth Action Plan 2012-2020 and will indisputably enhance the position of Europe in the global ERP industry and Healthcare sector. HEMACONN is a disrupting solution promoted by EID srl, a leader Italian company specialized organizational IT tools. The solution, which is already backed by many prospective clients, targets small to medium HCF, and is expected to be used by 40 HCFs in Europe (Italy, Germany, Austria, Holland, Scandinavia, Spain, UK, France, and Portugal) within three years after its commercialization, yielding €8.15M in total gross profits.

Keywords: enterprise resource planning software,administrative,health facility,hospital,plug in and go,interconnection,integration
Crimean-Congo Haemorrhagic Fever Vaccine (CCHFVaccine)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Preventing disease
Action type: Research and Innovation actions
Countries involved: Germany,Germany,Germany,Türkiye,Türkiye,Sweden,Bulgaria,Sweden,France,United States,Tajikistan,United Kingdom,Kosovo
Call: Vaccine development for malaria and/or neglected infectious diseases (H2020-SC1-2016-RTD, 2016)
Start date: 2017-01-01
End date: 2023-12-31
Duration (months): 84.0
Total project cost (EUR): 6255909.8
EU funding (EUR): 5979607.3
Participants: 15
Project status: SIGNED

Natural epidemics and outbreaks of emerging viral epidemics are growing problems internationally. The general aim of the CCHFVaccine project is to develop and deliver a vaccine, which can significantly increase our capacity to control the situation of Crimean Congo Haemorrhagic fever (CCHF) disease on a global basis. The proposed work program on CCHF virus aims to build a multidisciplinary research network, able to deliver vaccine candidates, methods and procedures eligible for clinical trials, with a special focus on prevention. Thanks to the background, unique facilities and tools available among the consortium participants, CCHFVaccine will deliver tools for countering the threat of this infection in Europe and endemic areas of the world. This work program will attempt to fill gaps in CCHFV virus research on immunology and vaccinology. To achieve this overall aim, an intensive work plan will be put in place with the following specific objectives: i) to produce vaccine candidates, ii) to bring several unique animal models into front line vaccine research, iii) to validate and bring the most promising vaccine candidates to clinical trials, iv) to ensure that an immune mediated protection is adequately understood, v) to perform clinical trials at Phase I and ensure a strategy for the effective deployment and utilization in resource-poor countries, and vi) to link this project to public health bodies, NGOs and vaccine companies. The proposed CCHFVaccine project will succeed in bringing together selected competitive advantages such as: operating capacity with appropriate facilities (state-of-the-art BSL-4s) and the only animal BSL-4 -with capacity to challenge domestic animals in Europe, highly experienced researchers in the development and evaluation of vaccine candidates, authorities and entities of human and animal health, clinical samples from endemic countries, and an international network proven to be functional by the previous EU-funded CCHFever and EDENext.

Keywords: emerging viral zoonosis,crimean congo haemorrhagic fever,vaccine,animal models
Design, manufacture and deliver a high performance, low cost, low weight Nacelle Structure for Next Generation Tilt-Rotor (NGCTR) (TRAIL)

Framework: Horizon 2020 — Societal Challenges
Programme: Smart, green and integrated transport
Theme: Public-private partnerships
Destination: Clean Sky 2
Action type: Innovation actions
Partnership: CS2 (Art-187)
Countries involved: Italy,Poland,Poland,Poland,France,France,Czechia,Netherlands,United Kingdom
Call: Design, manufacture and deliver a high performance, low cost, low weight Nacelle Structure for Next Generation TiltRotor (NGCTR) - Technology Demonstrator (TD) (H2020-CS2-CFP09-2018-02, 2018)
Start date: 2019-10-01
End date: 2023-11-30
Duration (months): 50.0
Total project cost (EUR): 6091140.33
EU funding (EUR): 5199438.13
Participants: 10
Project status: SIGNED

The aim of the Clean Sky 2 topic JTI-CS2-2018-CFP09-FRC-01-26 “Design, manufacture and deliver a high performance, low cost, low weight Nacelle Structure for Next Generation TiltRotor (NGCTR) - Technology Demonstrator (TD)” is to develop innovative: lightweight materials, architecture, technologies, fire resistant materials, control of structural borne vibration to be applied on the Nacelle of the NGCTR under supervision of Leonardo Helicopters Division. TRAIL Consortium shall meet the target by introducing advanced composite materials and designing highly integrated monocoque structure of the Nacelle with use of OoA (Out of Autoclave) and VARTM (Vacuum Assisted Resin Transfer Method) manufacturing techniques. In the frame of the project lightweight hybrid firewalls (composite with elastomeric coating) shall be investigated to produce lighter structure. The project will also deal with novel means to damp structure borne vibration and noise through application of viscoelastic materials into the NGCTR TD Engine Nacelle design. The realization of the project shall lead to significant weight of the structure and number of parts reduction. It shall also show that decreasing manufacturing costs and time is possible and lead to introduction of technologies which shall reduce environmental impact of air transport and aviation industry.

Keywords: next generation civil tilt rotor,engine nacelle,design,manufacturing
AXVIRIUM BIOACTIVE TECNOLOGY_ The first medical device able to eliminate the fluids biological hazard (ABT)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Italy
Call: SME instrument (H2020-SMEInst-2018-2020-1, 2018)
Start date: 2019-02-01
End date: 2019-07-31
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

The aim of the project is to validate the technical and economic feasibility of AXVIRIUM BIOACTIVE TECNOLOGY (ABT) an innovative biomedical device, based on the Adantium® Plus and Axivirium BIOACTIVE® molecules, enable to cut biological risks, improve efficiency and reduce cost of health care biomedical fluids disposal. Medical waste is posing a growing problem worldwide resulting in nearly 7000 tons every day of infectious /hazardous medical waste and 10 billion euro annually in disposal cost across the European health care industry. According to the World Health Organisation (WHO), incorrect and improper management of healthcare biological fluids can have direct impacts on the community, individuals working in health care facilities, and the natural environment. It estimated that at world level accidents caused by not proper biological risks management accounted for 66,000 cases of infection with the hepatitis B virus, 16,000 cases of infection with hepatitis C virus and 200 to 5,000 cases of HIV infection amongst the personnel of health-care facilities. Compared to competitors ABT is the unique solution able to reach 100% degradation of RNases almost in real time and completely sterilize biological fluids. This imply saving operational cost up to 20%, decreasing occupational diseases by 39% and reducing cross- nosocomial infection by 14%. In 2018, the valuation of the global fluid management market was EUR 10 billion and is anticipated to reach EUR 18 billion by 2022, at a positive CAGR of 4.8% in the next three years. The estimated market potential for ABT is about 21 million euro and we estimate to hire 23 high skilled employees. The feasibility study comprises an investigation of market structures, segments and barriers, a customer survey and product validation, the identification of key commercial partners and the development of an IP strategy.
Biological rhythms: Do they cointegrate? (BioCointegration)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Mathematics
Countries involved: Denmark
Call: Individual Fellowships (H2020-MSCA-IF-2019, 2019)
Start date: 2021-09-01
End date: 2023-08-31
Duration (months): 24.0
Total project cost (EUR): 207312.0
EU funding (EUR): 207312.0
Participants: 1
Project status: SIGNED

Many biological systems can be seen as networks of interconnected oscillating units. Unraveling how they interact, coordinate and influence each other in a random environment is essential for understanding systems such as the dynamic brain. The problem is that the current statistical methods are insufficient for solid data analysis. To solve this problem, I will elaborate the methodology of cointegration analysis, which has been applied mainly in econometrics, to provide a principled statistical framework for analyzing experimental data from neuronal systems. I will work on this project under the supervision of Professor Susanne Ditlevsen at the University of Copenhagen (UCPH).

Keywords: cointegration,biological oscillators,coupling,eeg data
Early detection of cervical cancer in hard-to-reach populations of women through portable and point-of-care HPV testing (ELEVATE)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Treating and managing disease
Action type: Research and Innovation actions
Countries involved: Spain,Ecuador,Germany,Spain,Belgium,Portugal,Brazil,Mexico,United Kingdom
Call: Translational collaborative cancer research between Europe and the Community of Latin American and Caribbean States (CELAC) (H2020-SC1-2018-Single-Stage-RTD, 2018)
Start date: 2019-01-01
End date: 2024-12-31
Duration (months): 72.0
Total project cost (EUR): 3999310.0
EU funding (EUR): 3301990.0
Participants: 9
Project status: SIGNED

Cervical cancer is the 4th most common cancer in women worlThe ELEVATE project sets a multidisciplinary team comprising manufactures and experts from Europe and the Community of Latin American and Caribbean States, to improve the global adequacy and coverage of cervical cancer screening, particularly to specific populations of women that by not being regularly screened (hard-to-reach populations) are at higher-risk to develop cervical cancer. Although Cervical cancer is still the fourth most common cancer in women worldwide, with up to 85% of the burden occurring in developing countries, preventive vaccination against human papillomavirus and early detection of precancer in screening programs has shown to be successful in reducing cancer incidence and mortality.1–3 However, different challenges hamper a global implementation of such programs and are in the base of women’s non-attendance to screening. This highlights the lack of reflection of ethnic, cultural and resource differences from different populations in current cervical cancer screening. In ELEVATE it is proposed to conduct social science investigations to identify hard-to-reach women in Belgium, Brazil, Ecuador and Portugal, to address their barriers to screening and to design strategies to make primary screening more accessible to them, and therefore, contribute to reduce the global burden of cervical cancer. This will be complemented with fundamental and technological research to develop an efficient and marketable test for the combined genomic and proteomic detection of high-risk HPV infections in those populations. The test will be made portable, low-cost, compatible with self-sampling, point-of-care and generate rapid and easy-to-understand results, without relying on electrical outlets or trained health personnel. Integrant part of the proposal is also to infer and disseminate the societal, economic implications of the developed strategies using a hard-to-reach community-based participatory research.

Keywords: cervical cancer,screening,hard to reach populations,genotyping,proteomics,point of care,portable,user friendly,low cost,community based research
5G Enhanced Mobile Broadband Access Networks in Crowded Environments (5G-Enhance)

Framework: Horizon 2020 — Industrial Leadership
Programme: Information and Communication Technologies
Action type: Research and Innovation actions
Countries involved: Germany,Finland,Belgium,Finland
Call: 5G and beyond (H2020-EUJ-2018, 2018)
Start date: 2018-07-01
End date: 2021-03-31
Duration (months): 33.0
Total project cost (EUR): 1498045.0
EU funding (EUR): 1498045.0
Participants: 4
Project status: CLOSED

The 5G era will offer diverse services and applications beneficial to societies in Europe and Japan, such as connected cars, eHealth, smart factory, and public safety. The development of the air interfaces (AIs) have followed to paths: the evolutionary path and the revolutionary path. This leads to a variety of possible AIs. An operator will only own a subset of the overall suite of AIs, increasing the need to enhance network performance significantly. Considering these needs, the focus of the 5G-Enhance project is on the definition and evaluation of interoperable 5G eMBB and efficient network solutions in dense area. 5G-Enhance will develop, plan and execute large scale trial activities on actual testbeds in EU and Japan. 5G-Enhance will execute two large scale trials with eMBB in crowded environments (dense area) to show the feasibility of the applications based on 5G network. The focus is on two specific applications in the context of enabling healthy lifestyle: The first application is 3D remote class for a real-time surgery that will be implemented in the Demo-1 (Trial 1).The second application is ad-hoc outdoor sport event to be implemented in the Demo-2 (Trial 2). The two demonstrations have different requirements. Demo-1, requires very high data rate, and supporting many users with low mobility and Demo-2 requires high data rate and supporting a massive number of users with high mobility. Integrated trial between Japanese and European partners will demonstrate the interoperability between Japanese and European facilities. 5G-Enhance will develop innovative mobile broadband technologies in order to enhance existing solutions towards better provision of 5G KPIs in dense eMBB scenarios. 5G-Enhance employs two key components, namely flexible and scalable network design and implementation and enhanced spectrum resource management.

Keywords: embb,dynamic tdd,multi connectivity,spectrum and network sharing techniques,micro operator